VA
NBIX icon

Vident Advisory’s Neurocrine Biosciences NBIX Stock Holding History

Vident Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.25M Buy
13,348
+11,351
+568% +$1.68M 0.02% 650
2026
Q1 		$263K Buy
1,997
+366
+22% +$48.6K ﹤0.01% 1570
2025
Q4 		$231K Sell
1,631
-221
-12% -$32K ﹤0.01% 1487
2025
Q3 		$260K Sell
1,852
-29
-2% -$3.93K ﹤0.01% 1457
2025
Q2 		$236K Buy
1,881
+57
+3% +$6.54K ﹤0.01% 1422
2025
Q1 		$202K Buy
+1,824
New +$231K ﹤0.01% 1449
2024
Q3 		– Sell
-2,613
Closed -$360K – 1500
2024
Q2 		$360K Sell
2,613
-95,141
-97% -$13M 0.01% 1054
2024
Q1 		$13.5M Buy
97,754
+95,219
+3,756% +$13M 0.28% 134
2023
Q4 		$334K Sell
2,535
-152
-6% -$17.5K 0.01% 956
2023
Q3 		$302K Buy
+2,687
New +$283K 0.01% 898

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vident Advisory's NBIX Position: Q2 2026 in Review

Vident Advisory increased its Neurocrine Biosciences (NBIX) stake by 568% in Q2 2026, buying an estimated $1.68M and bringing the position to 13,348 shares worth $2.25M. The position accounts for 0.02% of the portfolio, ranked #650.

Vident Advisory first reported a position in NBIX in Q3 2023 and has held it in 10 quarters since. The position peaked at $13.5M in Q1 2024. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Vident Advisory held 13,348 shares of Neurocrine Biosciences worth $2.25M as of Q2 2026.
  • Vident Advisory bought 11,351 Neurocrine Biosciences shares in Q2 2026, an estimated $1.68M.
  • Neurocrine Biosciences made up 0.02% of Vident Advisory's portfolio in Q2 2026, its #650 holding.
  • Vident Advisory first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 10 quarters since.
  • Vident Advisory's Neurocrine Biosciences position peaked at $13.5M in Q1 2024.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.